Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 05 August 2024

Created: 05 August 2024

Last Updated: 05 August 2024

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease and cancer, today announced that Fierce Biotech has named it as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising biotechnology companies in the industry.

Posted: 2024-08-05 10:05:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024 - Newscast

XGEN Venture closes $190M fund with plans to invest in early-stage biotech, medtech firms

Wed, 18 Dec 2024 12:55:00 GMT Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. | Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and ...

Novotech Named a Fierce CRO Award Winner in the Excellence in Clinical Trial Management and Global Operations Categories

Mon, 16 Dec 2024 05:05:00 GMT Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and ...

2 Boston-area biotechs shed staff, fuse to form genetic medicines company nChroma Bio

Wed, 11 Dec 2024 02:59:00 GMT Two Boston-area biotechs are shedding staff and merging together to form a new genetic medicines company. | Chroma Medicines and Nvelop Therapeutics are fusing their names and science to launch ...

CTI Recognized for Outstanding Patient Recruitment and Retention at 2024 Fierce Biotech CRO Awards

Tue, 10 Dec 2024 16:00:00 GMT CTI Clinical Trial & Consulting Services (CTI), a leading global, privately held full-spectrum research service provider, has been awarded the Outstanding Patient Recruitment and Retention honor at ...

Belharra's tide falls as the chemoproteomics biotech lays off 21 workers

Mon, 09 Dec 2024 12:52:00 GMT Small-molecule biotech Belharra Therapeutics is implementing a workforce reduction that will impact 21 people. | The layoffs will allow Belharra to extend its cash runway “to achieve key inflection ...